Kathleen Gondek

Summary

Affiliation: Bayer HealthCare
Country: USA

Publications

  1. ncbi request reprint Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels
    Kathleen Gondek
    Bayer Corporation, West Haven, CT 06516, USA
    J Clin Oncol 25:5087-93. 2007
  2. pmc Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA)
    Diane J Wild
    Oxford Outcomes Ltd, Old Barn, Jericho Farm, Cassington, Oxford, OX29 4SZ, UK
    Health Qual Life Outcomes 3:42. 2005
  3. ncbi request reprint Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire
    Darren Clayson
    Oxford Outcomes Ltd, Oxford, UK
    BJU Int 96:350-9. 2005
  4. ncbi request reprint The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners
    Dana Britt DiBenedetti
    Research Triangle Institute, NC, USA
    Eur Urol 48:503-11. 2005
  5. ncbi request reprint Responsiveness and minimum important differences for the erection quality scale
    Raymond C Rosen
    Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, USA
    J Urol 178:2076-81. 2007
  6. ncbi request reprint Patient-reported outcomes assessment in cancer trials: taking stock, moving forward
    Joseph Lipscomb
    Emory University, Atlanta, GA 30322, USA
    J Clin Oncol 25:5133-40. 2007
  7. ncbi request reprint Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
    David Cella
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    J Support Oncol 4:191-9. 2006
  8. ncbi request reprint Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer
    Ronald Bukowski
    CCF Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
    Am J Clin Oncol 30:220-7. 2007
  9. doi request reprint The identification of benefit in medical intervention: an overview and suggestions for process
    Paul E Stang
    Research and Development, Johnson and Johnson Pharmaceuticals, Titusville, NJ, USA
    Am J Ther 15:495-503. 2008

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels
    Kathleen Gondek
    Bayer Corporation, West Haven, CT 06516, USA
    J Clin Oncol 25:5087-93. 2007
    ..Collecting PRO data can enhance our understanding of cancer burden and the impact of interventions on patients' lives...
  2. pmc Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA)
    Diane J Wild
    Oxford Outcomes Ltd, Old Barn, Jericho Farm, Cassington, Oxford, OX29 4SZ, UK
    Health Qual Life Outcomes 3:42. 2005
    ..To validate a questionnaire to assess the activity impairment associated with uncomplicated urinary tract infection (uUTI)...
  3. ncbi request reprint Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire
    Darren Clayson
    Oxford Outcomes Ltd, Oxford, UK
    BJU Int 96:350-9. 2005
    ..To develop and validate a self-administered questionnaire to assess the 'severity' and 'bothersomeness' of the most frequently reported signs and symptoms of uncomplicated urinary tract infection (uUTI)...
  4. ncbi request reprint The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners
    Dana Britt DiBenedetti
    Research Triangle Institute, NC, USA
    Eur Urol 48:503-11. 2005
    ..The development of the Treatment Satisfaction Scale (TSS) was previously reported (Kubin et al., 2004)...
  5. ncbi request reprint Responsiveness and minimum important differences for the erection quality scale
    Raymond C Rosen
    Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, USA
    J Urol 178:2076-81. 2007
    ..We evaluated the responsiveness and treatment sensitivity of the Erection Quality Scale, and provided further psychometric validation of this scale...
  6. ncbi request reprint Patient-reported outcomes assessment in cancer trials: taking stock, moving forward
    Joseph Lipscomb
    Emory University, Atlanta, GA 30322, USA
    J Clin Oncol 25:5133-40. 2007
    ....
  7. ncbi request reprint Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
    David Cella
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    J Support Oncol 4:191-9. 2006
    ..Thus, the FKSI-15 and FKSI-10 are reliable and valid symptom indices for evaluating kidney cancer patients...
  8. ncbi request reprint Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer
    Ronald Bukowski
    CCF Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
    Am J Clin Oncol 30:220-7. 2007
    ..The aim of the current study was to determine the impact of treatment with sorafenib versus placebo on renal cancer symptoms and quality of life (QOL)...
  9. doi request reprint The identification of benefit in medical intervention: an overview and suggestions for process
    Paul E Stang
    Research and Development, Johnson and Johnson Pharmaceuticals, Titusville, NJ, USA
    Am J Ther 15:495-503. 2008
    ..As the emphasis is on transparency, relevance, applicability, and communication, this approach to assessing benefit should maximize the impact of these data to all stakeholders and decision makers...